Australia markets closed

GSK Jan 2025 18.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
As of 04:18PM EDT. Market open.
Full screen
Previous close0.0500
Open0.0500
Bid0.0000
Ask0.0000
Strike18.00
Expiry date2025-01-17
Day's range0.0500 - 0.0500
Contract rangeN/A
Volume7
Open interest86
  • Bloomberg

    GSK’s New Vaccine Kept the Boss in Her Job — and an Activist at Bay

    (Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer of GSK Plc found her remedy in a product almost 60 years in the making.Most Read from BloombergHims Debuts $199 Weight-Loss Shots at 85% Discount to WegovyIran State TV Says ‘No Sign of Life’ at Helicopter Crash SiteJamie Dimon Says Succession at JPMorgan Is ‘Well on the Way’One of the Last Big Bears on Wall Street Turns Bullish on US StocksFlorida’s 125% Surge in Property-

  • Reuters

    GSK whistleblower claims drugmaker cheated US government over Zantac cancer risk

    (Reuters) -GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug. In a whistleblower complaint filed on Monday, Valisure said GSK violated the federal False Claims Act by hiding the risks for nearly four decades while Medicare, Medicaid and other health programs covered billions of dollars of prescriptions. The New Haven-based lab said its testing in 2019 revealed that Zantac, also known as ranitidine, could form a cancer-causing carcinogen known as NMDA and was therefore "unfit for human consumption."

  • Evening Standard

    FTSE 100 Live 17 May: LandSec shares fall on results, GSK in £1.25bn final Haleon stake sale

    GSK and Land Securities are in the FTSE 100 spotlight after the drugs giant sold its final Haleon shares and the property firm posted results. The sale of GSK’s remaining 4% stake raised £1.25 billion, having held 13% following its 2022 demerger of the Panadol and Sensodyne business. Land Securities revealed a smaller full-year loss of £341 million amid “robust” rental growth across its estate.